vorapaxar
Merck’s vorapaxar gains long-awaited FDA approval
May 9, 2014Sales and Marketing Boehringer, FDA, Merck, lilly, vorapaxar, zontivity
Merck’s heart drug vorapaxar has finally been given the FDA go-ahead after looking dead in the water less than two …
Reprieve for Merck’s vorapaxar
January 16, 2014Sales and Marketing FDA, Merck, heart, vorapaxar
An FDA committee has voted that Merck’s troubled heart drug vorapaxar should be approved by the US regulator. The advisory …
Fate of Merck’s vorapaxar still unclear
February 8, 2012Medical Communications, Sales and Marketing Merck, vorapaxar
Merck & Co’s blood thinner vorapaxar, designed to prevent blood clots and reduce heart attacks, is still causing bleeding in …
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
Merck drops oral anticoagulant
March 25, 2011Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar
Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …
Merck suffers late-stage blow to vorapaxar
January 18, 2011Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar
An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
